RPL17调节乳腺癌的进展,伴随着MAPK信号激活
Yu Cai1,2, Hao Liu3, Guobing Yin4
1Department of Breast and Thyroid Surgery, Second Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, 400010, China.
核糖体蛋白L17 (RPL17) 在乳腺癌 (BC) 中过度表达,并驱动瘤生长和转移. 抑制RPL17可能为BC治疗提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 乳腺癌 (BC) 是全球癌症死亡的主要原因.
- 识别新的分子点对于有效的BC治疗至关重要.
研究的目的:
- 为了研究核糖体蛋白L17 (RPL17) 在乳腺癌中的作用.
- 探索RPL17作为BC的潜在治疗点.
主要方法:
- 在BC组织和细胞系中分析RPL17表达.
- 在BC细胞系中使用RPL17淘汰和过度表达的功能研究.
- 细胞增殖,迁移,入侵,细胞亡和MAPK信号的评估.
主要成果:
- 在BC组织和细胞系中,RPL17的表达显著升高.
- RPL17淘汰赛抑制BC细胞的增殖,迁移,入侵和粘附,同时增加细胞亡.
- RPL17淘汰赛降低了MAPK信号传递和上皮层-介质细胞过渡 (EMT).
- 过度表达RPL17增强BC细胞的攻击性,并通过MAPK信号传递促进EMT.
结论:
- 在乳腺癌中,RPL17起到瘤基因的作用.
- 在促进BC进展方面,RPL17起着至关重要的作用.
- RPL17是乳腺癌的潜在治疗点.
更多相关视频
07:13Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
Published on: March 26, 2014
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
相关概念视频
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
MAPK Signaling Cascades
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Negative Regulator Molecules
